Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24820794 | 0.92 | CRBN (0.74) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30738744 | 0.92 | CRBN (0.74) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL30958184 | 0.91 | CRBN (0.72) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25939463 | 0.91 | CRBN (0.76) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29414323 | 0.89 | CRBN (0.84) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24735212 | 0.89 | CRBN (0.84) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046081 | 0.89 | CRBN (0.84) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24827976 | 0.89 | CRBN (0.72) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22737960 | 0.89 | CRBN (0.72) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29877407 | 0.88 | CRBN (0.66) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233974-A | Indolone derivative and application thereof | 康百达（四川）生物医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| WO-2024017372-A1 | INDOLONE DERIVATIVE AND USE THEREOF | 成都百裕制药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-01 | — | — | US | disclosed |
| WO-2022187419-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-115023267-A | Spirocyclic androgen receptor protein degrading agents | 密歇根大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| EP-4031241-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | The Regents Of The University Of Michigan (US) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022011205-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, NR5A1, ESRRA | CRBN 2117/4885DDB1 1353/4885ALDH1A1 132/4885 |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | AR, CYP19A1, ESRRA | CRBN 1276/4885DDB1 1291/4885ALDH1A1 231/4885 |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | CRBN 945/4885DDB1 309/4885ALDH1A1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.